93 related articles for article (PubMed ID: 9309776)
1. Designer drugs: pipe-dreams or realities?
Gutteridge WE
Parasitology; 1997; 114 Suppl():S145-51. PubMed ID: 9309776
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
4. The current status of antiparasite chemotherapy.
Croft SL
Parasitology; 1997; 114 Suppl():S3-15. PubMed ID: 9309765
[TBL] [Abstract][Full Text] [Related]
5. Cancer Drug Development: New Targets for Cancer Treatment.
Curt GA
Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
[TBL] [Abstract][Full Text] [Related]
6. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
7. Importance of molecular computer modeling in anticancer drug development.
Geromichalos GD
J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
[TBL] [Abstract][Full Text] [Related]
8. Opportunities and challenges in antiparasitic drug discovery.
Pink R; Hudson A; Mouriès MA; Bendig M
Nat Rev Drug Discov; 2005 Sep; 4(9):727-40. PubMed ID: 16138106
[TBL] [Abstract][Full Text] [Related]
9. Recent progress in biomolecular engineering.
Ryu DD; Nam DH
Biotechnol Prog; 2000; 16(1):2-16. PubMed ID: 10662483
[TBL] [Abstract][Full Text] [Related]
10. Developing drugs for parasitic diseases.
Andreopoulos S
Science; 2003 Apr; 300(5618):430-1. PubMed ID: 12702858
[No Abstract] [Full Text] [Related]
11. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
12. Beware the Medical-Industrial Complex.
Stevens CW; Glatstein E
Oncologist; 1996; 1(4):IV-V. PubMed ID: 10388005
[TBL] [Abstract][Full Text] [Related]
13. [The origin of informed consent].
Mallardi V
Acta Otorhinolaryngol Ital; 2005 Oct; 25(5):312-27. PubMed ID: 16602332
[TBL] [Abstract][Full Text] [Related]
14. Control of human parasitic diseases: Context and overview.
Molyneux DH
Adv Parasitol; 2006; 61():1-45. PubMed ID: 16735161
[TBL] [Abstract][Full Text] [Related]
15. Looking into the future.
Potts M
Plan Parent Rev; 1983; 3(2):3-5. PubMed ID: 12265636
[TBL] [Abstract][Full Text] [Related]
16. The state of innovation in drug development.
Kola I
Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690
[TBL] [Abstract][Full Text] [Related]
17. Advances in drug discovery and biochemical studies.
Kita K; Shiomi K; Omura S
Trends Parasitol; 2007 May; 23(5):223-9. PubMed ID: 17383234
[TBL] [Abstract][Full Text] [Related]
18. Drug discovery and development for neglected parasitic diseases.
Renslo AR; McKerrow JH
Nat Chem Biol; 2006 Dec; 2(12):701-10. PubMed ID: 17108988
[TBL] [Abstract][Full Text] [Related]
19. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
[TBL] [Abstract][Full Text] [Related]
20. Antibacterial drug discovery: is it all downhill from here?
Projan SJ; Shlaes DM
Clin Microbiol Infect; 2004 Nov; 10 Suppl 4():18-22. PubMed ID: 15522036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
